Date updated:04-27-2009
No description available

-
NVAX
Novavax - $3.27
- +0.93%
- $3.31
Novavax (NVAX): NVAX can produce a vaccine from an emergent strain of flu virus in 12 weeks according to the CEO. Currently in Phase II trials, the FDA could give then emergency authorization power

-
BCRX
Biocryst Pharmace - $7.57
- -3.07%
- $7.88
BioCryst Pharmaceuticals (BCRX): BCRX is currently in Phase I testing (thus highly unlikely to get authorization power from the FDA) for drugs that block enzymes involved in cancer, viral infections, cardiovascular diseases, and autoimmune diseases.

-
AVII
Avi Biopharma - $1.66
- +2.47%
- $1.62
AVI Biopharma (AVII): AVII is in the process with a joint venture with the Department of Defense’s Transformational Medical Technologies Initiative, with the goal of developing drugs for cardiovascular diseases.

-
DVAX
Dynavax Technolog - $1.30
- +0.78%
- $1.30
Dynavax Technologies (DVAX): DVAX is currently in Phase II testing of its universal flu vaccine, the company also has several other drugs in its pipeline, and joint ventures with GlaxoSmithKline (GSK), Astra Zeneca, and Novartis. DVAX has $1.7 in cash per share, and no debt.

-
SVA
Sinovac Biotech - $7.54
- +1.21%
- $7.40
Sinovac Biotech (SVA): SVA is a Chinese based biotech company that engages in the sale of vaccines that protect against human infectious in mainland China. The company’s principal drug ‘Anflu’ provides a split virus influenza vaccine.

-
ADLS
Adls - $0.00
- N/A
- $N/A
Advanced Life Sciences Holdings (ADLS): ADLS’s leading drug called ‘Cethromycin’ is a once-a-day treatment for pneumonia. Currently under review by the FDA, ADLS has tested Cethromycin in Phase III testing.

-
QDEL
Quidel Corporatio - $13.13
- +3.30%
- $12.83
Quidel Corp (QDEL): QDEL makes the QuickVue test which is used during flu season. Recently the company reported a wider then expected loss because of a mild flue season, which led to weak demand for their flu test kit.

-
GNBT
Generex Biotechno - $0.55
- -1.79%
- $0.575
Generex Biotechnology (GNBT): GNBT operates several different sprays for weight-loss, and type I and type II diabetes. GNBT is also working on Phase I and Phase II testing for SARS, and Influenza.
- Top Professional Portfolios
- 1. Fidelity Contrafund - ...
- 2. Navellier & Associ...
- 3. Calamos Advisors
- 4. Argus Management
- 5. Robert Karr - Joho Cap...
- show all
- Top Do-It-Yourself Portfolios
- » Joseph Russell Portfolio 1
- » Albo's First Portfolio
- » Darrell Werth Portfolio 1
- » Echo5Joker's Portfolio
- » jgroov Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Dec. 4, 2009 According to Jim Cramer, the bears need a new line of argument. He said the doom-and-gloomers have been very quiet of late, but...
By Fred Fuld Posted on Dec. 3, 2009 Everyone can appreciate the security offered by a regular income, whether in the form of a paycheck or retirement check -- or a divi...
Posted on Dec. 3, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...
By Roberto Pedone Posted on Dec. 3, 2009 The traders of CNBC’s “Fast Money” think the path of least resistance for the stock market remains to the upside. On Tues...
A. Penny stocks web sites are full of scam
artists. I would stay away from them and
do your own research. db
A. The only one I own : SLX,
too hard pick a winner out all of them
These are the stocks from Jim Cramer's Dec. 4 Lightning Round. We list the stocks on which he is BULLISH and BEARISH.... more
Here is the stock list of some of the largest % losers from Dec. 4, 2009. more
Here is a list of some of the biggest stocks that hit 52-week lows on Dec. 4, 2009. more













04/28/2009 19:03 PM CDT Asked by interslice
will there be any significant movers tomorrow?